Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis

Table 2

Pooled response rate for CAR-T cell therapy according to subgroup analyses.

Subgroups	Studies	Pooled RR	95% CI	Heterogeneity ()	value between groups
Lymph depletion
Yes	11	11%	4%-20%	54%	0.638
No	11	8%	1%-19%	62%
Transfection method
Lentiviral	11	10%	3%-21%	56%	0.935
Retroviral	7	9%	2%-22%	69%
Cell culture duration
<14 days	11	11%	3%-23%	67%	0.806
≥14 days	6	13%	3%-28%	50%
Persistence of CAR-T cells
<4 weeks	10	12%	3%-25%	69%	0.777
≥4 weeks	9	10%	3%-19%	41%
Transfection efficacy
<50%	10	10%	1%-16%	62%	0.335
≥50%	7	14%	3%-30%	61%
Total cell dose
<10^9	13	11%	4%-19%	49%	0.939
≥10^9	7	11%	2%-27%	66%
Administration of IL-2
Yes	6	11%	1%-29%	70%	0.827
No	12	9%	3%-20%	60%